Nectar lifesciences Limited has successfully completed the extinguishment of 3,00,00,000 equity shares through its tender offer buyback program. The pharmaceutical company announced the completion of this corporate action on January 21, 2026, following the buyback process that concluded earlier this month.

Buyback Program Details

The tender offer buyback was conducted from December 31, 2025, to January 6, 2026, through the stock exchange mechanism. The company repurchased shares at ₹27.00 per equity share, representing a total buyback value of ₹81.00 crores for the 3 crore shares acquired.

Share Capital Reconciliation

The extinguishment process has resulted in a significant reduction in the company's share capital structure. The buyback was executed in compliance with Regulation 24(iv) read with Regulation 11 of the Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018.

Extinguishment Process

All 3,00,00,000 equity shares were extinguished in dematerialized form through National Securities Depository Limited (NSDL). The shares were processed through Master Capital Services Ltd. (DP ID: IN301143) on January 20, 2026. No equity shares were tendered or extinguished in physical form during this buyback program.

The extinguishment was certified by multiple parties including the company's management, secretarial auditor P. Chadha & Associates, and registrar KFin Technologies Limited. NSDL confirmed the debit of 30,000,000 shares from the depository system on January 20, 2026.

Regulatory Compliance

The buyback program was initiated following the public announcement dated December 4, 2025, published on December 5, 2025, along with a corrigendum published on December 10, 2025. The letter of offer was issued on December 29, 2025, providing shareholders with the necessary details for participation in the tender offer.

The entire process was conducted in accordance with SEBI (Buyback of Securities) Regulations, 2018, and SEBI (Depository and Participants) Regulations, 2018. The company has submitted all required documentation and confirmations to both NSE (Symbol: NECLIFE) and BSE (Scrip Code: 532649) as part of its regulatory obligations.

Nectar Lifesciences Limited has successfully completed its share buyback program, purchasing 3 crore equity shares at ₹27 per share for a total consideration of ₹81 crore. The buyback, which concluded on January 6, 2026, witnessed significant investor interest with oversubscription of 2.05 times the target amount.

Buyback Program Details

The company's tender offer period commenced on December 31, 2025, and closed on January 6, 2026. The buyback was executed through the designated stock exchange mechanism, with NSE serving as the designated exchange. Settlement of all accepted bids was completed by January 13, 2026, through the Indian Clearing Corporation Limited and NSE Clearing Limited.

Investor Response and Allocation

The buyback received an overwhelming response from shareholders, with 11,981 valid bids received for 6.16 crore equity shares, representing 205.22% of the shares offered for buyback. The response was particularly strong in both categories of shareholders.

Major Participants

Several institutional investors participated significantly in the buyback program. Rajasthan Global Securities Private Limited emerged as the largest participant, with their accepted shares representing 14.59% of the total buyback.

Impact on Capital Structure

Following the buyback completion, Nectar Lifesciences' paid-up share capital will reduce from ₹22.43 crore to ₹19.43 crore, subject to the extinguishment of the bought-back shares. The extinguishment process is currently underway and expected to complete by January 22, 2026.

Shareholding Pattern Changes

The buyback will result in an increase in promoter shareholding from 44.90% to 51.84%, while the total number of shares outstanding will decrease from 22.43 crore to 19.43 crore shares.

The successful completion of this buyback program demonstrates strong management confidence in the company's prospects and provides enhanced value to shareholders through the premium buyback price and improved shareholding concentration.